Latest Articles
Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer - MSN
Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer MSN
Published: June 2, 2026, 12:41 a.m.
Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer - Medical Xpress
Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer Medical Xpress
Published: June 1, 2026, 8 p.m.
Immunotherapy Addition Demonstrates Sustained Survival Benefits in - Bioengineer.org
Immunotherapy Addition Demonstrates Sustained Survival Benefits in Bioengineer.org
Published: May 29, 2026, 11:56 p.m.
Potential Immunotherapy After Immunotherapy in Select Endometrial Cancer Populations - CancerNetwork
Potential Immunotherapy After Immunotherapy in Select Endometrial Cancer Populations CancerNetwork
Published: May 25, 2026, 1:56 p.m.
Endometriosis and ovarian cancer risk.
To critically evaluate the evidence linking endometriosis to ovarian cancer, with particular focus on endometrioid and clear cell histologic subtypes, and to inform risk stratification and patient counseling.
Published: May 12, 2026, midnight
Managing Progression After Immunotherapy in Endometrial Cancer - OncLive
Managing Progression After Immunotherapy in Endometrial Cancer OncLive
Published: May 5, 2026, 12:07 p.m.
High response rates in platinum-resistant ovarian cancer with immunotherapy agents - MSN
High response rates in platinum-resistant ovarian cancer with immunotherapy agents MSN
Published: April 20, 2026, 8:14 a.m.
Impact of Overall Survival Data on Immunotherapy Selection in Endometrial Cancer - Pharmacy Times
Impact of Overall Survival Data on Immunotherapy Selection in Endometrial Cancer Pharmacy Times
Published: April 17, 2026, 12:30 p.m.
High Response Rates in Platinum-Resistant Ovarian Cancer With Immunotherapy Agents - MedPage Today
High Response Rates in Platinum-Resistant Ovarian Cancer With Immunotherapy Agents MedPage Today
Published: April 16, 2026, 7:11 p.m.
Epigenetic Compound Library Screen Identifies Ibrutinib as an Inhibitor of Ovarian Clear Cell Carcinoma Viability.
Ovarian clear cell carcinoma (OCCC) is an endometriosis-associated ovarian cancer subtype. Somatic mutations in OCCC are reported in ARID1A, PIK3CA, and the TERT promoter (TERTp), as well as less commonly …
Published: April 10, 2026, midnight
Link copied to clipboard!